The ELISA results showed that both ginsenoside Rg3 and gefitinib tended to reduce EGFR content in lung tissues of mice with carcinoma in situ according to the regimen of continuous administration alone, combined continuous administration, and interval sequential administration of gefitinib/ginsenoside Rg3, respectively, but only the EGFR content in lung tissues of mice with the regimen of interval sequential administration of gefitinib/ginsenoside Rg3 was significantly lower than the control group (Figure 8H, p < 0.05). The gene discussed is EGFR; the disease is in situ carcinoma.